Correlation of elevated serum CXCL16 and severity of acute coronary syndromes in male elders

National Medical Journal of China

Volumn 91, Issue 46, 2011, Pages 3271-3274

  Zhuge, Xin ^a   Wang, Li Li ^a   Sun, Ning ^a   Zhang, Yun ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Aged; Chemotactic factors; Coronary disease

Indexed keywords

CXCL16 CHEMOKINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; STABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHEMOKINES, CXC; CORONARY ARTERY DISEASE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; RECEPTORS, SCAVENGER; RISK FACTORS;

EID: 84871318198     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2011.46.009     Document Type: Article

References (18)

1. Ross R. Atherosclerosis is an inflamatory disease. Am Heart J, 1999, 138: S419-S420.
2. Lusis AJ. Atherosclerosis. Nature, 2000, 407: 233-241.
3. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol, 2007, 27: 15-26.
4. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol, 2004, 29: 439-493.
5. Matloubian M, David A, Engel S, et al. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol, 2000, 1: 298-304.
6. Minami M, Kume N, Shimaoka T, et al. Expression of SR-PSOX, a novel cell-surface scavenger receptor for phosphatidylserine and oxidized LDL in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol, 2001, 21: 1796-1800.
7. Wuttge DM, Zhou X, Sheikine Y, et al. CXCL16/SR-PSOX is an interferon-gamma-regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb VascBiol, 2004, 24: 750-755.
8. Smith C, Halvorsen B, Otterdal K, et al. High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins. Cardiovasc Res, 2008, 79: 195-203.
9. Sheikine Y, Bang CS, Nilsson L, et al. Decreased plasma CXCL16/SR-PSOX concentration is associated with coronary artery disease. Atherosclerosis, 2006, 188: 462-466.
10. Lehrke M, Millington SC, Lefterova M, et al. CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. J Am Coll Cardiol, 2007, 49: 442-449.
11. Mitsuoka H, Toyohara M, Kume N, et al. Circulating soluble SR-PSOX/CXCL16 as a biomarker for acute coronary syndrome-comparision with high-sensitivity C-reactive protein. J Atheros Throm, 2009, 16: 586-593.
12. van Lieshout AW, Popa C, Meyer-Wentrup F, et al. Circulating CXCL16 is not related to circulating oxLDL in patients with rheumatoid arthritis. Biochem Biophys Res Commun, 2007, 355: 392-397.
13. Yi GW, Zeng QT. Circulating CXCL16 is related to the severity of coronary artery stenosis. Archives of Medical Research, 2008, 39: 531-535.
14. Sun Y, Chang ZW, Zhang SJ. Increased serum CXCL16 level is a marker for acute coronary syndromes. Archives of Medical Research, 2008, 39: 332-337.
15. 2010, 8: 756-760.
16. 2011, 17: 19-21.
17. Jansson AM, Aukrust P, Ueland T, et al. Soluble CXCL16 predicts long-term mortality in acute coronary syndromes. Circulation, 2009, 119: 3181-3188.
18. Yang HL, Xu YY, Du LF, et al. Chemokine SR-PSOX/CXCL16 expression in peripheral blood of patients with acute coronary syndrome. Chin Med J, 2008, 121: 112-117.